Log on / register
BioMed Central home | Journals A-Z | Feedback | Support | My details

This article is part of the supplement: Abstracts of the Ninth International Congress on Drug Therapy in HIV Infection .

Open AccessOral presentation

O125 Impact of efavirenz and nevirapine on pharmacokinetics of lopinavir/ritonavir as tablets and capsules in African patients

C Kityo1, AS Walker2, F Lutwana3, F Ssali4, R Nalumenya3, D Tumukunde4, J Kawiya5, P Munderi6, A Reid7, CF Gilks8, DM Gibb2 and SH Khoo9

CRC, Uganda, Uganda

MRC Clinical Trials Unit, London, UK

Infectious Diseases Institute, Mulago, Uganda

Joint Clinical Trials Unit, London, UK

Joint Clinical Research Centre, Kampala, Uganda

MRC/UVRI Research Unit on AIDS, Entebbe, Uganda

University of Zimbabwe, Harare, Zimbabwe

Imperial College, London, UK

Liverpool University, Liverpool, UK

corresponding author email

from Ninth International Congress on Drug Therapy in HIV Infection
Glasgow, UK. 9–13 November 2008

Journal of the International AIDS Society 2008, 11(Suppl 1):O10doi:10.1186/1758-2652-11-S1-O10

Published: 10 November 2008

First paragraph (this article has no abstract)

With NNRTI, the recommended dose of lopinavir/r (LPV/r) is 4 capsules (533/133 mg) BD. With LPV/r tablets, the closest doses are 2 tablets (400/100 mg) BD or 3 tablets [tabs] (600/150 mg) BD. Improved bioavailability of the tablet suggests that 2 tabs BD should be sufficient, but PK data are few and generally from Caucasians.


© 1999-2010 BioMed Central Ltd unless otherwise stated. Part of Springer Science+Business Media.